Huadong Medicine Co., Ltd (SHE:000963)
China · Delayed Price · Currency is CNY 33.75
-0.46 (-1.34%)
Apr 28, 2026, 3:04 PM CST
Huadong Medicine Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Net Income | 3,502 | 3,414 | 3,512 | 2,839 | 2,499 | 2,302 |
Depreciation & Amortization | 1,012 | 1,012 | 855.03 | 809.56 | 705.55 | 591.56 |
Other Amortization | 27.59 | 27.59 | 9.73 | 9.69 | 6.65 | 5.96 |
Loss (Gain) From Sale of Assets | -2.26 | -2.26 | 5.46 | -4.32 | -8.26 | 0.03 |
Asset Writedown & Restructuring Costs | 81.43 | 81.43 | 25.19 | 5.14 | -22.6 | 8.02 |
Loss (Gain) From Sale of Investments | 75.92 | 75.92 | 82.8 | 202.15 | 115.62 | 52.91 |
Provision & Write-off of Bad Debts | 136.91 | 136.91 | 112.18 | 25.76 | 68.69 | 41.69 |
Other Operating Activities | -23.85 | 83.24 | 87.18 | 121.32 | 137.61 | 132.51 |
Change in Accounts Receivable | -673.32 | -673.32 | -1,980 | -968.97 | -2,095 | -775.57 |
Change in Inventory | -828.39 | -828.39 | -498.85 | 213.85 | -491.52 | 18.09 |
Change in Accounts Payable | 1,054 | 1,054 | 1,566 | 685.55 | 1,450 | 770.58 |
Change in Other Net Operating Assets | 0.52 | 0.52 | 20.98 | 43.01 | 7.24 | - |
Operating Cash Flow | 4,226 | 4,246 | 3,749 | 3,929 | 2,382 | 3,170 |
Operating Cash Flow Growth | 24.27% | 13.25% | -4.59% | 64.96% | -24.86% | -7.08% |
Capital Expenditures | -1,199 | -1,574 | -1,728 | -1,607 | -1,193 | -819.1 |
Sale of Property, Plant & Equipment | 11.42 | 21.1 | 19.76 | 10.85 | 15.43 | 79.16 |
Cash Acquisitions | - | - | -620.24 | -134.06 | -415.09 | -819.6 |
Divestitures | - | - | - | - | - | -113.37 |
Investment in Securities | -254.88 | -186.88 | 112.84 | -115.24 | -948.91 | -357.5 |
Other Investing Activities | 27.11 | 70.46 | 45.23 | 94.52 | 106.2 | 43.72 |
Investing Cash Flow | -1,415 | -1,670 | -2,170 | -1,751 | -2,436 | -1,987 |
Long-Term Debt Issued | - | 4,135 | 5,251 | 4,876 | 4,975 | 2,259 |
Total Debt Issued | 3,977 | 4,135 | 5,251 | 4,876 | 4,975 | 2,259 |
Long-Term Debt Repaid | - | -5,165 | -4,263 | -5,729 | -4,653 | -2,405 |
Total Debt Repaid | -4,933 | -5,165 | -4,263 | -5,729 | -4,653 | -2,405 |
Net Debt Issued (Repaid) | -956.28 | -1,030 | 987.92 | -852.43 | 322.13 | -146.03 |
Issuance of Common Stock | - | - | - | 10.63 | 104.65 | - |
Repurchase of Common Stock | -13.81 | -13.81 | -4.13 | - | - | - |
Common Dividends Paid | -1,712 | -1,692 | -1,702 | -594.21 | -576.49 | -460.11 |
Other Financing Activities | -18.49 | -86.53 | -31.28 | 42.66 | 50.01 | -161.31 |
Financing Cash Flow | -2,700 | -2,822 | -749.66 | -1,393 | -99.71 | -767.45 |
Foreign Exchange Rate Adjustments | -8.65 | -7.59 | -47 | 5.95 | -9.77 | 7.11 |
Net Cash Flow | 101.59 | -254.23 | 781.99 | 791.25 | -163.23 | 422.73 |
Free Cash Flow | 3,027 | 2,671 | 2,021 | 2,323 | 1,189 | 2,351 |
Free Cash Flow Growth | 100.76% | 32.17% | -12.98% | 95.40% | -49.44% | 21.26% |
Free Cash Flow Margin | 6.87% | 6.13% | 4.82% | 5.72% | 3.15% | 6.80% |
Free Cash Flow Per Share | 1.73 | 1.52 | 1.15 | 1.33 | 0.68 | 1.34 |
Cash Interest Paid | - | - | - | - | 0.62 | 0.95 |
Cash Income Tax Paid | 2,955 | 2,918 | 2,563 | 2,552 | 3,018 | 1,539 |
Levered Free Cash Flow | 2,438 | 2,051 | 1,255 | 1,862 | 604.48 | 2,104 |
Unlevered Free Cash Flow | 2,486 | 2,104 | 1,315 | 1,934 | 679.51 | 2,147 |
Change in Working Capital | -584 | -584 | -940.75 | -78.95 | -1,121 | 35.45 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.